NEW YORK (GenomeWeb News) — Upstream Biosciences has hired Genpathway to use its chromatin immunoprecipitation assays in its cancer biomarker-validation studies, Upstream Bio said today.
Genpathway will use its assays to “help elucidate critical parameters involving specific gene transcription factors and pathways” and provide “critical information for the next phase of Upstream's program to validate its first two cancer biomarkers and drug response assay,” according to Upstream.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.

A phylogenetic analysis indicates two venomous Australian spiders are more closely related than thought, the International Business Times reports.

In Science this week: CRISPR-based approach for recording cellular events, and more.

A new company says it will analyze customers' genes to find them a suitable date, though Smithsonian magazine says the science behind it might be shaky.

Sponsored by
Swift Biosciences

This webinar will discuss an optimized protocol for methyl-CpG binding domain sequencing (MBD-seq), which enables comprehensive, adequately powered, and cost-effective large-scale methylome-wide association studies (MWAS) of almost all 28 million CpG sites in the genome.

Sponsored by
Dovetail Genomics

Proximity ligation technology generates multi-dimensional next-generation sequencing data that is proving to solve unmet needs in genomic research.